SynCo Bio Partners enters the Japanese market as it signs its first agreement with a Japanese pharmaceutical company
SynCo Bio Partners B.V. announced that it has expanded its business into a new geographical market, with the signing of a contract to manufacture a live biotherapeutic for an emerging Japanese pharmaceutical company.
The undisclosed company’s product is an live biotherapeutic based anticancer drug. The project will first involve a consultancy phase, during which SynCo will assist the client with in-house process development. The developed process will then be transferred to SynCo’s Amsterdam facility and scaled-up, prior to GMP manufacture for Phase I clinical trials, including fermentation, formulation and aseptic filling.
“We are extremely pleased to be working our first Japanese partner” commented SynCo’s CEO, Mr. Pierre Warffemius ”this is an exciting project for a leading Japanese business and I look forward to the successful completion of GMP manufacture, in the field of live biotherapeutics. This contract represents SynCo’s entry into the growing Japanese biotherapeutics market and is reflective of our continuing success in a very competitive GMP contract manufacturing market.”
Other news from the department business & finance
